Accessibility Menu
Pluri logo

Pluri(NASDAQ) PSTI

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-94%
1 Year-65%
1 Month-16%
Pluri last closing stock price
MetricPriceDate
Last closeUSD 1.782026-07-24
Pluri stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.3%USD 1.862026-07-17
1 month-16.04%USD 2.122026-06-24
3 month-46.79%USD 3.352026-04-24
Year to date-40.47%USD 2.992025-12-31
1 year-65.17%USD 5.112025-07-24
3 year-70.33%USD 6.002023-07-25
5 year-93.51%USD 27.442021-07-23
Since inception-99.89%USD 1,600.002003-04-16

Pluri Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.17M

Net Income (TTM)

-$10.19M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 12, 2022

PSTI News

557 doctor visit

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

Maxx ChatskoApr 28, 2020
multiple lines up

Here's Why Pluristem Therapeutics Jumped Over 28% Today

Maxx ChatskoApr 24, 2020

Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.

George Budwell, PhDMar 6, 2014

Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today

Leo SunNov 13, 2013

Why Pluristem Therapeutics Is Poised to Plunge

BRIAN PACAMPARAJan 16, 2013

3 Horrendous Health-Care Stocks This Week

Keith SpeightsDec 29, 2012

Are Short-Sellers Onto Something at Pluristem Therapeutics?

Rich DupreyNov 29, 2012

This Week in Biotech: Part 2

Sean WilliamsNov 10, 2012
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pluri

Pluri develops cell therapies from human placentas to treat serious health conditions. Its products help patients recover from muscle injuries and immune system problems. The company also supports food and agriculture businesses with cell-based technology.

Products and Services

  • Cell Therapy Products: Placenta-based treatments for muscle injuries, immune disorders, and blood cell recovery. (Revenue share not disclosed)
  • PLX-PAD: Therapy in late-stage trials for muscle recovery after hip surgery and for severe lung conditions.
  • PLX-R18: Product for patients with poor blood cell recovery after transplants and for radiation exposure.
  • Immunotherapy: Placenta-derived immune cells for cancer and immune system diseases.
  • CDMO Services: Manufacturing services for other companies’ cell therapies, mainly for research and clinical use. (Major revenue driver in 2025)
  • Food and AgTech: Cultivated coffee, cacao, and meat products for food companies and agriculture partners.

Growth and Expansion

  • Launched PluriCDMO™ cell therapy manufacturing business in January 2024.
  • Acquired 71% of Kokomodo (cultivated cacao) in 2025 for $4.5 million in shares.
  • Expanded Ever After Foods joint venture with Tnuva in 2024 to include fish and seafood.
  • Partnered with ICL Group for agricultural biostimulant delivery in 2024.
  • Moved Ever After Foods to its own facility in March 2025.

What Makes Pluri Stand Out

Pluri uses a unique 3D cell expansion platform to produce cells at scale. Its in-house manufacturing facility supports both its own products and third-party clients. The company applies its technology across healthcare, food, and agriculture, creating multiple revenue streams.

Five Things You Need to Know

  • Revenue was $316,000 in QQ1 2026, down 3.1% from QQ1 2025.
  • Gross profit was $115,000 in QQ1 2026, down 42.5% year-over-year.
  • Net loss was $6 million in QQ1 2026, 4.3% higher than QQ1 2025.
  • Cash and short-term deposits totaled $27.5 million as of March 31, 2025.
  • Accumulated deficit reached $435.5 million by March 31, 2025.

Bottom Line

Pluri has diversified from cell therapies into food and agriculture technology. The company faces ongoing losses but continues to expand its business model and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

127

CEO

Yaky Yanay, CPA

Website

www.pluri-biotech.com

Headquarters

Haifa, 3508409, IL

PSTI Financials

Key Financial Metrics (TTM)

Gross Margin

36.72%

Operating Margin

-1908.63%

Net Income Margin

-870.11%

Return on Equity

79.27%

Return on Capital

N/A

Return on Assets

-65.34%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$430.00K

Operating Income

-$22.35M

EBITDA

-$16.03M

Operating Cash Flow

$3.51M

Capital Expenditure

-$2.13M

Free Cash Flow

$1.38M

Cash & ST Invst.

$3.42M

Total Debt

$6.21M

Pluri Performance Analysis

Pluri annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 234,000N/A
20232023-06-30USD 287,00022.6%
20242024-06-30USD 326,00013.6%
20252025-06-30USD 1,336,000309.8%
Pluri sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3014.8%
Q12025-09-30-35.5%
Q22025-12-31-37.3%
Q32026-03-31-15.7%
Pluri annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -10.25N/A
20232023-06-30USD -6.18-39.7%
20242024-06-30USD -3.99-35.5%
20252025-06-30USD -3.56-10.6%
Pluri sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-89.4%
Q12025-09-3063.5%
Q22025-12-31-9.2%
Q32026-03-3122.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$167.00K

-60.9%

Gross Profit

$56.00K

-58.8%

Gross Margin

33.53%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

153

N/A

Net Income

-$6.17M

+2.6%

EBITDA

$128.00K

+102.1%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$3.42M

N/A

Total Debt

$6.21M

-0.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.60M

-0.7%

Short Term Debt

$614.00K

+2.5%

Return on Assets

-65.34%

N/A

Return on Invested Capital

1.36%

N/A

Free Cash Flow

-$4.56M

+6.6%

Operating Cash Flow

-$4.51M

-4.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MGTAMagenta Therapeutics, Inc.
$0.70-7.74%
RNTXRein Therapeutics Inc.
$0.79-1.10%
EYENEyenovia, Inc.
$7.56+3.99%
STSASatsuma Pharmaceuticals, Inc.
$1.10+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
NUNu Holdings
$14.09-0.01%

Questions About PSTI

What is the current price of Pluri?

Pluri is trading at N/A per share.

What is the 52-week range for Pluri?

Over the past 52 weeks, Pluri has traded between N/A and N/A.

How much debt does Pluri have?

As of the most recent reporting period, Pluri reported total debt of $33.63M.

How much cash does Pluri have on hand?

Pluri reported $3.65M in cash and cash equivalents in its most recent financial results.

What is Pluri’s dividend yield?

Pluri does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services